# Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

> **NCT05321602** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 89 (actual)

## Conditions studied

- Schizophrenia
- Psychotic Disorders
- Mood Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Mental Disorders
- Antipsychotic Agents
- Tranquilizing Agents
- Central Nervous System Depression
- Physiological Effects of Drugs
- Psychotropic Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action

## Interventions

- **DRUG:** LY03010 156 mg treatment group, deltoid
- **DRUG:** LY03010 156 mg treatment group, gluteal
- **DRUG:** LY03010 351 mg treatment group, deltoid
- **DRUG:** LY03010 351 mg treatment group, gluteal

## Key facts

- **NCT ID:** NCT05321602
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-08
- **Primary completion:** 2022-09-23
- **Final completion:** 2022-10-23
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2024-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05321602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05321602, "Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05321602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*